Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma(†)

OBJECTIVE: This single-arm, open-label, Phase II study evaluated the efficacy and safety of single-agent bevacizumab, a monoclonal antibody against vascular endothelial growth factor, in Japanese patients with recurrent malignant glioma. METHODS: Patients with histologically confirmed, measurable gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagane, Motoo, Nishikawa, Ryo, Narita, Yoshitaka, Kobayashi, Hiroyuki, Takano, Shingo, Shinoura, Nobusada, Aoki, Tomokazu, Sugiyama, Kazuhiko, Kuratsu, Junichi, Muragaki, Yoshihiro, Sawamura, Yutaka, Matsutani, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448378/
https://www.ncbi.nlm.nih.gov/pubmed/22844129
http://dx.doi.org/10.1093/jjco/hys121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448378/
https://www.ncbi.nlm.nih.gov/pubmed/22844129
http://dx.doi.org/10.1093/jjco/hys121

Ejemplares similares